Search

Simbrinza

Simbrinza

Manufacturer:

Novartis

Distributor:

Zuellig
/
Firma Chun Cheong
Concise Prescribing Info
Contents
Per mL Brinzolamide 10 mg, brimonidine tartrate 2 mg
Indications/Uses
Decrease elevated IOP in adult patients w/ open-angle glaucoma or ocular HTN for whom monotherapy is insufficient.
Click to view Simbrinza detailed prescribing information
Dosage/Direction for Use
Adult & elderly 1 drop in affected eye/s bd.
Click to view Simbrinza detailed prescribing information
Overdosage
View Simbrinza overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Concomitant use of MAOIs, antidepressants eg, TCA & mianserin. Severe renal impairment, hyperchloraemic acidosis. Neonates & infants <2 yr.
Click to view Simbrinza detailed prescribing information
Special Precautions
Ocular allergic reactions, delayed ocular hypersensitivity. Not recommended in patients w/ narrow-angle glaucoma. Careful monitoring of patients w/ compromised corneas. Avoid wearing contact lenses. Patients w/ severe or unstable & uncontrolled CV disease; depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension or thromboangiitis obliterans. Reports of acid-base disturbances. Hepatic & renal impairment. Concomitant use w/ antihypertensives &/or cardiac glycosides. Contains benzalkonium Cl. May impair ability to perform tasks requiring alertness &/or physical coordination. Pregnancy & lactation. Not recommended in childn & adolescents.
Click to view Simbrinza detailed prescribing information
Adverse Reactions
Ocular hyperaemia & allergic type reactions, dysgeusia. Somnolence, dizziness; keratitis, eye pain, ocular discomfort, blurred vision, abnormal vision, conjunctival blanching; dry mouth.
Click to view Simbrinza detailed prescribing information
Drug Interactions
Contraindicated w/ MAOIs & antidepressants which affect noradrenergic transmission (eg, TCAs & mianserin). TCAs may blunt the ocular hypotensive response. Additive or potentiating effect w/ CNS depressants (eg, alcohol, barbiturates, opiates, sedatives or anaesth). Use w/ caution in patients taking drugs affecting metabolism & uptake of circulating amines (eg, chlorpromazine, methylphenidate, reserpine, SNRIs). Reduced pulse & BP w/ concomitant use of antihypertensives & cardiac glycosides. Use w/ caution when initiating concomitant adrenergic receptor agonists or antagonists eg, isoprenaline, prazosin. Additive effect on known systemic effects of carbonic anhydrase inhibition w/ oral carbonic anhydrase inhibitor. Inhibited metabolism w/ CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clotrimazole, ritonavir & troleandomycin).
Click to view Simbrinza detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Simbrinza detailed prescribing information
Storage
View Simbrinza storage conditions for details to ensure optimal shelf-life.
Description
View Simbrinza description for details of the chemical structure and excipients (inactive components).
Action
View Simbrinza mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antiglaucoma Preparations
ATC Classification
S01EC54 - brinzolamide, combinations ; Belongs to the class of carbonic anhydrase inhibitors. Used in the treatment of glaucoma.
Presentation/Packing
Form
Simbrinza eye drops suspension
Packing/Price
5 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in